What are the opening hours?

Monday 09:00 - 18:00 Tuesday 09:00 - 18:00 Wednesday 09:00 - 18:00 Thursday 09:00 - 18:00 Friday 09:00 - 18:00

Oncode Scientific Sdn Bhd

Home
Malaysia
Shah Alam
Oncode Scientific Sdn Bhd

Oncode Scientific Sdn Bhd
201501029484 (1154805-X)

Leading the Precision Medicine Revolution in Asia

Since 2015, Oncode Scientific Sdn Bhd has emerged as a trailblazer in the realm of precision medicine, setting new benchmarks in cancer molecular diagnostics. Our multidisciplinary team, comprising top-tier experts from molecular science and clinical practice, brings together decades of experience in medical diagnostics and research. At our cuttin

g-edge facilities in Malaysia, we spearhead one of Asia’s most pioneering precision medicine initiatives, specializing in both solid tumors and hematologic cancers. Our relentless pursuit of innovation drives us to constantly challenge the status quo, exceeding clinical and diagnostic standards to deliver groundbreaking medical solutions. Oncode is dedicated to transforming healthcare—advancing disease prevention, early detection, and targeted intervention. With a commitment to excellence, we provide world-class molecular diagnostic services that are both accessible and revolutionary, empowering the global community to embrace the full potential of precision medicine.

06/08/2025

📢 MTDC x Oncode: A Bold Step Forward for Malaysia’s Healthcare Innovation

🧬 Witnessed by MOSTI Minister YB Chang Lih Kang
🎥 Full coverage via BERNAMA TV:
https://www.youtube.com/watch?v=ofu_XJTxq_w

06/08/2025

🌟 𝗣𝗶𝗼𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵 — 𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿.

A bold new chapter begins as the Malaysian Technology Development Corporation (𝗠𝗧𝗗𝗖) and 𝗢𝗻𝗰𝗼𝗱𝗲 enter into a 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽, witnessed by 𝗬𝗕 𝗧𝘂𝗮𝗻 𝗖𝗵𝗮𝗻𝗴 𝗟𝗶𝗵 𝗞𝗮𝗻𝗴, Kementerian Sains, Teknologi dan Inovasi (MOSTI).

Held at 𝗠𝗧𝗗𝗖 𝗛𝗲𝗮𝗱𝗾𝘂𝗮𝗿𝘁𝗲𝗿𝘀, the signing ceremony marked a significant milestone in strengthening Malaysia’s deep-tech ecosystem — unlocking the future of 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀, 𝗔𝗜-𝗽𝗼𝘄𝗲𝗿𝗲𝗱 𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲, and 𝗻𝗲𝘅𝘁-𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻.

𝗘𝘃𝗲𝗻𝘁 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:
🗣️𝗪𝗲𝗹𝗰𝗼𝗺𝗶𝗻𝗴 𝘀𝗽𝗲𝗲𝗰𝗵 by 𝗧𝘀. 𝗛𝗷 𝗠𝗼𝗵𝗮𝗺𝗺𝗮𝗱 𝗛𝗮𝘇𝗮𝗻𝗶 𝗛𝗷 𝗛𝗮𝘀𝘀𝗮𝗻, Group CEO of MTDC
🗣️𝗩𝗶𝘀𝗶𝗼𝗻-𝘀𝗵𝗮𝗿𝗶𝗻𝗴 by 𝗔𝘀𝘀𝗼𝗰. 𝗣𝗿𝗼𝗳. 𝗗𝗿. 𝗟𝗶𝗺 𝗦𝘂 𝗪𝗲𝗻, Founding CEO of Oncode
🗣️𝗦𝗽𝗲𝗰𝗶𝗮𝗹 𝗮𝗱𝗱𝗿𝗲𝘀𝘀 by 𝗬𝗕 𝗧𝘂𝗮𝗻 Chang Lih Kang, Minister of MOSTI
✍️ 𝗦𝗶𝗴𝗻𝗶𝗻𝗴 𝗼𝗳 𝘁𝗵𝗲 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗶𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁
🔬𝗢𝗻𝗰𝗼𝗱𝗲 𝗖𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝘀𝗵𝗼𝘄𝗰𝗮𝘀𝗲, unveiling how technology meets purpose in real-world diagnostics
📰 𝗣𝗿𝗲𝘀𝘀 𝗰𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 with national media

This partnership represents more than capital investment — it reflects 𝗮 𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗰𝗼𝗺𝗺𝗶𝘁𝗺𝗲𝗻𝘁 𝘁𝗼 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 that improves patient outcomes, empowers clinicians, and positions Malaysia as a leader in health technology.

💡 With MTDC’s support, 𝗢𝗻𝗰𝗼𝗱𝗲 𝗶𝘀 𝗽𝗼𝗶𝘀𝗲𝗱 𝘁𝗼 𝘀𝗰𝗮𝗹𝗲, transforming breakthrough technologies into real-world, 𝗹𝗶𝗳𝗲-𝗰𝗵𝗮𝗻𝗴𝗶𝗻𝗴 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 for Malaysia and beyond.

🤝 𝗠𝗧𝗗𝗖 — 𝘄𝗵𝗼𝗹𝗹𝘆 𝗼𝘄𝗻𝗲𝗱 𝗯𝘆 𝗞𝗵𝗮𝘇𝗮𝗻𝗮𝗵 𝗡𝗮𝘀𝗶𝗼𝗻𝗮𝗹 𝗕𝗲𝗿𝗵𝗮𝗱 and operating under the 𝗽𝘂𝗿𝘃𝗶𝗲𝘄 𝗼𝗳 𝗠𝗢𝗦𝗧𝗜 — plays a pivotal role in nurturing Malaysia’s deep-tech landscape through strategic investments and technology commercialization. We are deeply honoured to welcome MTDC as our partner on this journey toward regional and global impact.

🙏 Heartfelt thanks to all our distinguished guests, partners, and media friends who joined us. Your presence made this milestone truly meaningful.

Here’s to building a healthier tomorrow — powered by deep tech and a shared vision for impact.

📣𝗜𝗻 𝘁𝗵𝗲 𝗡𝗲𝘄𝘀:
📰 [BERNAMA: MTDC Invests In Oncode To Boost Malaysia’s Healthtech And Deep Tech Ecosystems] Embedded URL: https://www.bernama.com/en/general/news.php?id=2453386&utm_source=chatgpt.com

📻 [BERNAMA News Channel / Radio: MTDC Meterai Perjanjian Pelaburan Perkasa Teknologi Kesihatan…] Embedded URL: https://www.nama.com.my/video/tvclip/2025/08/05/20250805_t60_btv-bb-1100pm_13.mp4

📺 [RTM: Misi MOSTI untuk memperkukuh ekosistem teknologi di Malaysia] Embedded URL: https://berita.rtm.gov.my/nasional/senarai-berita-nasional/senarai-artikel/misi-mosti-untuk-memperkukuh-ekosistem-teknologi-di-malaysia

📹 [Newswave: MTDC meterai perjanjian pelaburan perkasa teknologi kesihatan, ekosistem teknologi mendalam] Embedded URL: https://newswav.com/video/mtdc-meterai-perjanjian-pelaburan-perkasa-teknologi-kesihatan-ekosistem-tek-V2508_9ubKwR

10/07/2025

On 3rd July 2025, Oncode was honoured to host a Continuing Medical Education (CME) session with the Internal Medicine team at Hospital Sultan Abdul Aziz Shah (UPM).

During the session, we introduced the capabilities of 𝗢𝗻𝗰𝗼𝗱𝗲 𝗟𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝘆, showcased the 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗡𝗲𝘅𝘁-𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗶𝗻𝗴 (𝗡𝗚𝗦) across various cancer types through previous Oncode case reports, and shared insights on the 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝗰𝗲 𝗼𝗳 𝗴𝗲𝗿𝗺𝗹𝗶𝗻𝗲 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 for individuals with a family history of cancer.

Thank you to the dedicated clinicians who joined us in advancing precision oncology. We look forward to continued collaborations in driving better outcomes through data-driven care.

27/06/2025

As we welcome 1 Muharram and begin the Islamic New Year, let us reflect, renew, and rise with gratitude and purpose. 🌙

At Oncode Scientific, we continue our mission in advancing healthcare with compassion, innovation, and precision — one patient, one solution at a time.

Wishing you and your loved ones peace, good health, and new beginnings this Awal Muharram. 💙

20/06/2025

🚀 𝗦𝗵𝗮𝗽𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗛𝗲𝗮𝗹𝘁𝗵 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: 𝗢𝗻𝗰𝗼𝗱𝗲 𝗮𝘁 𝘁𝗵𝗲 𝗖𝗵𝗶𝗻𝗮-𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮 𝗜𝗻𝘁𝗲𝗿𝗱𝗶𝘀𝗰𝗶𝗽𝗹𝗶𝗻𝗮𝗿𝘆 𝗙𝗼𝗿𝘂𝗺

Oncode was honoured to participate as an 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗹𝗲𝗮𝗱𝗲𝗿 at the China-Malaysia Interdisciplinary Engagement Forum: Exploring the Frontiers of Life Sciences Together, hosted by the𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗼𝗳 𝗡𝗼𝘁𝘁𝗶𝗻𝗴𝗵𝗮𝗺 𝗡𝗶𝗻𝗴𝗯𝗼 𝗖𝗵𝗶𝗻𝗮 (𝗨𝗡𝗡𝗖) on June 4, 2025.

Our Founding CEO, 𝗔𝘀𝘀𝗼𝗰. 𝗣𝗿𝗼𝗳. 𝗗𝗿. 𝗟𝗶𝗺 𝗦𝘂 𝗪𝗲𝗻, joined distinguished 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿𝘀 𝗮𝗻𝗱 𝗮𝗰𝗮𝗱𝗲𝗺𝗶𝗰 𝗹𝗲𝗮𝗱𝗲𝗿𝘀 from the 𝗖𝗵𝗶𝗻𝗮 𝗕𝗲𝗮𝗰𝗼𝗻𝘀 𝗜𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗲 (𝗖𝗕𝗜) of UNNC and the 𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆 𝗼𝗳 𝗡𝗼𝘁𝘁𝗶𝗻𝗴𝗵𝗮𝗺 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮 (𝗨𝗡𝗠) to explore pioneering research and bold cross-border collaboration in life sciences and precision healthcare.

This high-impact forum brought together academia and industry to spark 𝗶𝗻𝘁𝗲𝗿𝗱𝗶𝘀𝗰𝗶𝗽𝗹𝗶𝗻𝗮𝗿𝘆 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻, foster 𝗱𝗲𝗲𝗽 𝗸𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲 𝗲𝘅𝗰𝗵𝗮𝗻𝗴𝗲, and ignite partnerships that bridge science with real-world solutions — all in pursuit of a healthier, smarter, and more connected global society.

We thank the organizers for championing this meaningful initiative between Malaysia and China. Oncode is proud to stand at the intersection of science and strategy — where innovation becomes impact.

14/06/2025

This Father’s Day, we honor the strength, care, and quiet courage of all fathers — the ones who support us, guide us, and stand strong through every challenge. 💙

At Oncode, we’re reminded that just like great dads, true care often happens behind the scenes — protecting, preventing, and pushing forward.

To all the amazing fathers in our lives and in healthcare — Happy Father’s Day!

01/06/2025

🎉 Official Launch: FLT3 Testing Copay Program 🎉

We’re proud to announce the launch of the FLT3 Testing Copay Program — a groundbreaking initiative by Oncode and Astellas Pharma, a leading pharmaceutical company from Japan, to expand access to precision diagnostics for relapsed or refractory acute myeloid leukemia (AML) patients in Malaysia’s public healthcare system.

More than a partnership, this program reflects a united effort across industry, clinical laboratories, government agencies, and healthcare providers — working together to close diagnostic gaps in hematologic oncology by making FLT3 genetic testing more accessible and affordable.

We were deeply honored to have YB Datuk Ts. Dr. Mohd Nor Azman Hassan, Deputy Secretary General (Technology Development), Kementerian Sains, Teknologi dan Inovasi (MOSTI), officiate the launch. Opening remarks were also delivered by Assoc. Prof. Dr. Lim Su Wen, Founding CEO of Oncode, and Mr. Nikhil Goyal, Business Unit Head of Oncology, Astellas Pharma Malaysia and Singapore.

Our heartfelt appreciation goes to our other distinguished guests from MOSTI ⁠Ts. Dr. Radin Zulhazmi bin Radin Abdul Halim and Pn. Siti Zuhaini binti Abd Samah, Malaysian Technology Development Corporation (MTDC), represented by En. Najib Khan, Pn. Munirah Abdullah Sani and En. Muhammad Haziq; Bioeconomy Corporation represented by Pn. Ts Soeraya Satem Ahmad and Pn. Dayana Mohamed Fadzil; and National Cancer Society Malaysia (NCSM) represented by En. Muhammad Radzi.

We are also grateful to the many leading haematologists and key opinion leaders from renowned hospitals across Malaysia who joined us at the launch. Your presence is a powerful reflection of the clinical leadership that is driving meaningful progress in cancer care.

To all clinicians, advocates, and partners walking this journey with us — thank you.

Through innovation, collaboration, and a shared commitment to patient care, we are paving the way toward equitable, life-saving cancer diagnostics.

Let’s continue to push the boundaries of what’s possible in precision oncology.

🔗 Read the full press release: https://www.oncodesc.com/oncode-and-astellas-launch-flt3-copay-program-to-enhance-access-to-aml-diagnostics-in-malaysia/

23/05/2025

🎉 Oncode Scientific is Now CAP Accredited! 🧬

On April 23, 2025, Oncode Laboratory was officially accredited by the College of American Pathologists (CAP) — one of the highest international recognitions for clinical laboratories.

This milestone follows a rigorous on-site inspection and reflects our unwavering commitment to quality, safety, and diagnostic excellence. With this, Oncode joins an elite group of laboratories worldwide recognized for meeting the highest standards in laboratory medicine.

💬 “This achievement reflects not only the standards we uphold, but the deeper purpose that drives our work,” shared our Founding CEO, Assoc. Prof. Dr. Lim Su Wen.

“I’m especially grateful to those who led this effort with unwavering commitment — Dr. Subramanian Yegappan (Lab Director), Dr. Kow Koon Kee (Operations & Quality Director), and Dr. Goh Share Yuan (Technical Director) — as well as every member of the Oncode team whose dedication made this possible.”

👏 We celebrate this not just as a milestone, but as a reflection of our purpose, which is to deliver diagnostics that are trusted, reliable, and truly make a difference in patient care.

🔗 Read the full press release: https://shorturl.at/61hVr

19/05/2025

Oncode is honoured to represent the Malaysian Technology Development Corporation (MTDC) as one of Malaysia’s leading tech companies at the MOSTI Exhibition Week and Business Matching Program, held at the Malaysia Pavilion, World Expo Osaka, Japan.

We are grateful to MTDC and the Kementerian Sains, Teknologi dan Inovasi (MOSTI) for the opportunity to showcase Oncode’s innovations in precision diagnostics on this global stage.

From engaging with distinguished Japanese industry leaders to connecting with Malaysian agencies, researchers, and decision-makers — the event sparked valuable conversations and potential collaborations across borders.

Special thanks to the Malaysia External Trade Development Corporation (MATRADE) for organizing this impactful national initiative.

This experience reaffirms Oncode’s commitment to purposeful innovation, strategic partnerships, and advancing healthcare through science.

10/05/2025

🌸 Happy Mother’s Day from all of us at Oncode 🌸

To the ones who give without asking, love without condition, and carry strength in silence — today, we celebrate you.

Thank you to all the mothers, in every form, for your unwavering grace, quiet courage, and infinite care. You are the heart of every family, and the soul of every healing journey.

💖 Wishing you a day filled with love, peace, and appreciation — you deserve nothing less.

07/05/2025

We were thrilled to participate in the Malaysia–Indonesia Biopartnering Program in Jakarta — a dynamic platform uniting pioneering minds in biotechnology and bio-based innovation from both countries. 🇲🇾🇮🇩

A heartfelt thank you to Bioeconomy Corporation for the kind invitation and for hosting such a purposeful and impactful event. It was truly inspiring to engage with innovators, industry leaders, and government representatives who are collectively shaping the future of our regional bioeconomy.

We were also honored to have our Founding CEO, Assoc. Prof. Dr. Lim Su Wen, shared Oncode’s story and vision during the session — highlighting how we’re advancing precision diagnostics and contributing to the growth of the biotech ecosystem in the region.

At Oncode, we’re proud to be part of this growing community — and excited to explore the cross-border collaborations and innovations ahead.

30/04/2025

Happy Labour Day from all of us at Oncode Scientific!

Today, we honour the strength, dedication, and passion that drives every hardworking individual—especially those advancing health and science every day.🫶🏻

Thank you for your tireless efforts. Let’s continue to build a healthier tomorrow, together!

Address

Lot 03-01, 3rd Floor. Hap Seng Business Park, No. 12, Persiaran Perusahaan, Unity Square. Seksyen 23, Shah Alam D. E.
Shah Alam
40300

Opening Hours

Monday	09:00 - 18:00
Tuesday	09:00 - 18:00
Wednesday	09:00 - 18:00
Thursday	09:00 - 18:00
Friday	09:00 - 18:00

Telephone

+60333100819

Website

http://www.oncodesc.com/

Alerts

Be the first to know and let us send you an email when Oncode Scientific Sdn Bhd posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Oncode Scientific Sdn Bhd:

Shortcuts

About Oncode

ONCODE Scientific Sdn Bhd was founded in 2015, by a strong knowledge-based management and operational team with the combination of more than 85 years of experience in the areas of medical diagnostics and scientific research. It’s aims to be a niche player specializing in Precision Medicine utilizing the techniques of Next Generation Sequencing (NGS), Sanger sequencing, Real-Time & Standard PCR technologies. The team comprises of scientists, geneticists, physicians, pharmacists, bioinformaticians and business veterans who aim to deliver the best quality and affordable molecular diagnostic solutions to the global community.

Oncode laboratory workflows and pipelines include internal and external validation quality controls for compliance with international standards of Good Laboratory Practice (GLP), ISO 15189, the Association for Molecular Pathology (AMP) and the College of American Pathologist (CAP).

The laboratory participates in external quality assurance and proficiency programs including the UK National External Quality Assurance System (UKNEQAS), The European Molecular Genetics Quality Network (EMQN) and the Royal College of Pathologists of Australasia (RCPA).

Oncode Mission

To provide quality diagnostic solutions to customers through the implementation of state-of-the-art laboratory setup designed to worldwide standards, recruitment of dedicated professionals and comprehensive reporting systems.

Oncode Objective

To be a regional one-stop molecular genetics solution center, delivering powerful diagnostic support and insight to medical professionals

关于恩可德

恩可德私人有限公司成立于2015年，由一支强大的知识型管理和运营团队组成，在医疗诊断和科学研究领域拥有超过85年的经验。它的目标是通过提供高科技的下一代基因测序(Next- Generation Sequencing, NGS), Sanger基因测序，实时和标准聚合酶链反(Polymerase-Chain Reaction，PCR) 技术，成为专注于精准医学的利基参与者。该团队由科学家，遗传学家,专科医生，药剂师，生物信息学家和商业资深人士组成，旨在为全球社区提供最优质，价格合理的分子诊断解决方案。

恩可德实验室工作流程和管道包括内部和外验证质量控制，以符合良好实验室规范(Good- Laboratory Practice, GLP)，国际标准化组织（ISO15189），分子病理学协会(Association of Molecular Pathology, AMP)和美国病理学家学会(College of American Pathologist, CAP)的国际标准。

该实验室参与外部质量保证和熟练程序，包括英国国家外部质量保证体系(United Kingdom National External Quality Assurance System, UKNEQAS)，欧洲分子遗传学质量网络(European Molecular Genetics Quality Network)和澳大利亚皇家病理学家学会(Royal College of Pathologists of Australasia, RCPA).

我们的使命

通过实施针对全球标准设计的最先进实验室设置，招聘专业人员和综合报告系统，为客户提供高质量的诊断解决方案。

我们的目标

成为区域性一站式分子遗传学解决方案中心，为医疗专业人员提供强大的诊断支持和洞察力

06/08/2025

06/08/2025

10/07/2025

27/06/2025

20/06/2025

14/06/2025

01/06/2025

23/05/2025

19/05/2025

10/05/2025

07/05/2025

30/04/2025

Address

Opening Hours

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category

About Oncode

关于恩可德